ArticleJournal for immunotherapy of cancer2023

Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.

Viktoria Marquardt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.